Weight loss medications: Where do they fit in?

Australian Family Physician

Volumn 35, Issue 8, 2006, Pages 576-579

  Dixon, John B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE; PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CHRONIC DISEASE; DRUG EFFECT; HUMAN; OBESITY; PHYSIOLOGY; REVIEW; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CHRONIC DISEASE; CYCLOBUTANES; DIETHYLPROPION; HUMANS; LACTONES; OBESITY; PHENTERMINE; WEIGHT LOSS;

EID: 33749081023     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG, Leibel RL. Is the energy homeostasis system inherently biased toward weight gain? Diabetes 2003;52:232-8.
2. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: National Health and Medical Research Council, 2003.
3. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293:1861-7.
4. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
5. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.
6. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.
7. Wirth A, Krause J. Long term weight loss with sibutramine: a randomised controlled trial. JAMA 2001;286:1331-9.
8. Wadden TA, Berkowitz RI, Womble LG, et al. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20.
9. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
10. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004;27:33-40.
11. Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 2005;7:254-62.
12. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29:277-302.
13. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomised clinical trials. Int J Obes Relat Metab Disord 2002;26:262-73.
14. Glazer G. Long term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;161:1814-24.
15. Norris SL, Zhang X, Avenell A, et al. Long term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005(2):CD004095.
16. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomised controlled trial. JAMA 2006;295:761-75.
17. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
18. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
19. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
20. McGuire MT, Wing RR, Klem ML, Seagle HM, Hill JO. Long term maintenance of weight loss: do people who lose weight through various weight loss methods use different behaviours to maintain their weight? Int J Obes Relat Metab Disord 1998;22:572-7.